Session Chair Profile

VP, Strategy and Marketing, DNAnexus
Biography

Brady brings over 15 years experience as an innovator and leader in the life sciences space as well as the hospital ACO and consumer health and wellness industries. Prior to DNAnexus, Brady was head of strategy and market development for Illumina with a special focus on Informatics and driving opportunities to use genetics data as clinical utility. Brady serves on the board of multiple non-profit organizations including the Global Alzheimer’s Association Interactive Network (GAAIN), Cancer Commons, Ci4CC, and is Co-Chair of the Advisory Board for the University of Washington Center for Commercialization (C4C). Brady is a graduate of University of Washington.

Session Abstract – PMWC 2018 Silicon Valley

Session Synopsis: Health care providers increasingly require multi-omic data sets, including phenotypic data informed by genomic data. Such data needs to be obtained in an economically sustainable way and made available on an agile user-friendly platform so that these data may inform clinical care and lead to health improvements.Pharmaceutical companies (“Pharmas”) are interested in obtaining datasets containing phenotypic/clinical and genomic information generated from patient cohorts of specific disease areas. Such datasets can help Pharma researchers identify drug targets or find biomarkers, validate hypotheses related to the interaction of genomics with disease or with specific therapies, and identify candidate populations for future clinical trials. Payers are also interested in the outcomes related to new discoveries and therapies in order to reimburse for these treatments. This session will focus on how both health care provider organizations, Pharmas and Payers are working toward solving these complex and challenging problems from a technical and business model perspective.